Who is sponsoring NCT04717154?

NCT04717154 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04717154?

Interventions in NCT04717154: Ipilimumab, Nivolumab.

What condition does NCT04717154 study?

NCT04717154 studies Prostatic Neoplasms, Castration-Resistant.

Is NCT04717154 still recruiting?

NCT04717154 is currently completed. Last updated 6 January 2026.

Last reviewed 2026-01-06 · How we verify

NCT04717154: INSPIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

Completed Phase 2 Last updated 6 January 2026

What this trial tests

Phase 2 trial testing Ipilimumab in Prostatic Neoplasms, Castration-Resistant in 69 participants. Completed in 18 December 2025.

Timeline

19 January 2021

Primary endpoint
15 August 2024

18 December 2025

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	69
Start date	19 January 2021
Primary completion	15 August 2024
Estimated completion	18 December 2025
Sites	1 location across Netherlands

Drugs / interventions tested

Ipilimumab — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Prostatic Neoplasms, Castration-Resistant — all drugs for Prostatic Neoplasms, Castration-Resistant →

Sponsor

Radboud University Medical Center

Who can join

18 and older, male only, with Prostatic Neoplasms, Castration-Resistant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the effects of 4 cycles of combinatory immunotherapy (ipilimumab and nivolumab), followed by monotherapy nivolumab in participants with immunogenic metastatic castration-resistant prostate cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, et al · · 2021 · cited 44× · PMID 34067105 · DOI 10.3390/cancers13092249
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
Rebuzzi SE, Rescigno P, Catalano F, Mollica V, et al · · 2022 · cited 40× · PMID 35267553 · DOI 10.3390/cancers14051245
The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
Xu P, Wasielewski LJ, Yang JC, Cai D, et al · · 2022 · cited 29× · PMID 35892678 · DOI 10.3390/biomedicines10081778
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
Maekawa S, Takata R, Obara W. · · 2024 · cited 27× · PMID 38339274 · DOI 10.3390/cancers16030523
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Nguyen CB, Reimers MA, Perera C, Abida W, et al · · 2024 · cited 24× · PMID 38787530 · DOI 10.1158/1078-0432.ccr-24-0400
The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue.
Di Donato M, Giovannelli P, Migliaccio A, Castoria G. · · 2023 · cited 23× · PMID 36941697 · DOI 10.1186/s13578-023-01008-4
Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management.
Hansen SB, Unal B, Kuzu OF, Saatcioglu F. · · 2024 · cited 21× · PMID 39629128 · DOI 10.7150/thno.100555

Verify or expand the search:

Other trials of Ipilimumab

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07293351 — A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Caboz · Phase 1, PHASE2 · recruiting
NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting

Other recruiting trials for Prostatic Neoplasms, Castration-Resistant

Currently open trials in the same condition.

NCT07225946 — A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc · Phase 3 · recruiting
NCT06706921 — 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer · Phase 4 · recruiting
NCT06353386 — Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip · Phase 1, PHASE2 · recruiting
NCT05743621 — Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · recruiting
NCT05393791 — Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC · Phase 2 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04717154 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 6 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04717154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing